The Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation (NHF) issued three new documents, all of which were adopted by NHF’s Board of Directors on March 4, 2021.
MASAC Document #264, which replaces Document #245, lays out a set of detailed recommendations for the diagnostic evaluation and management of girls and women presenting with symptoms of a bleeding disorder, including appropriate lab testing and additional considerations such as family history. It also recommends that females with bleeding disorders are provided access to the full complement of multidisciplinary services available at hemophilia treatment centers, including appropriate therapies, clinical management, genetic testing, and counseling.
MASAC Document #265, which replaces Document #251, includes recommendations for the diagnosis and management of women with bleeding disorders during pregnancy, labor, and delivery. The document also addresses the critical postpartum period with specific treatment recommendations designed to both mitigate the risk of bleeding-related complications in women and to enable the early diagnosis of affected infants.
MASAC Document #266, which replaces Document #244, is focused exclusively on the treatment of von Willebrand disease (VWD), the most common inherited bleeding disorder. It describes the current menu of therapies available to effectively treat individuals with VWD, including types 1, 2A, 2B, 2M, 2N and 3. The document also provides a series of detailed considerations for both the prescription of VWD therapies and for assessing patient responses to treatment, to both ensure efficacy and to avoid complications. NOTE: These recommendations were adapted from evidence-based guidelines developed collaboratively by the American Society of Hematology, the International Society on Thrombosis and Haemostasis, the World Federation of Hemophilia, and NHF.